Skip to main content
. 2018 Sep 7;4(3):102–108. doi: 10.1016/j.afos.2018.08.002

Table 2.

Baseline clinical characteristics.

Variable AI group (n = 48) PO group (n = 48)
Previous fracture Vertebral fracture (n = 2)
Radius fracture (n = 2)		 Vertebral fracture (n = 38)
Femoral neck fracture (n = 6)
Pelvic fracture (n = 2)
Complications Endometriosis (n = 2)
Myoma uteri (n = 2)
Hyperlipidaemia (n = 2)
Hypertension (n = 2)
Diabetes mellitus (n = 2)
Thyroid cancer (n = 2)		 Hyperlipidaemia (n = 6)
Hypertension (n = 4)
Asthma (n = 2)
Osteoarthrosis (n = 2)
Diabetes mellitus (n = 4)
Behcet disease (n = 2)

AI group, therapy of aromatase inhibitor-induced osteoporosis; PO group, patients of primary postmenopausal osteoporosis.